#ctlas

[cobaltsunflower]

CTLAS x Homestuck - Part 1: Client-Server

Brainrot combo comes again, so here goes my tentative ideas, with explanations of HS concepts. Continuing discussion and Q&A in comments or tags are encouraged!!!

4-PLAYER SBURB SESSION

Sburb: A Reality-altering video game, where the goal is escaping the destruction of one's planet, becoming gods, and creating a new universe.

"The game requires a bare minimum of two players to function properly, each acting as each other's server and client player." "The server is able to manipulate the environment around the client in a matter similar to that of The Sim." - MS Paint Adventure Wiki

The Client is the one to enter the game world, assisted by the Server.

Prior to entrance, the Client's location will be the one actively being hit by meteors and must act on a timeline to enter the game before impact.

Failure to connect the daisy-chain of players result in a failed session, in which the timeline is doomed and slowly erased from existence.

.

Order (Client-Server): Yvienne <- January <- Daughter <- Lariatte

1. [Yvienne <- January]

Canonically, these 2 are the first to meet, so I think in this AU Yvienne roped January into playing with her first, before getting the others in.

From HS canon, it seems that the first client is inevitably the leader of that session. Yvienne is the first client and leader, which fits with CTLAS how she's the glue that held their friend group together.

2. [January <- Daughter]

Then January meets Daughter, who is a major part in helping him improving his life and self-esteem. So Daughter is the Server to support January getting his shits together.

3. [Daughter <- Larriatte]

Loose connection here, but the point of relation is Larri learning from the upperclassmen before trying to establish connections with her classmates, and Daughter is one of them. So she would be his Server.

(Lmao I dug through my entire folder and this is like the only page with Larri and Daughter interacting)

4. [Lariatte <- Yvienne]

Ok now this is the meat and pie. I'm thinking of Larri's first time opening her field and then starry-eyed awaiting Yvienne to bring her out, but Yvienne wasn't sure she could do it. Larri's last stance when they couldn't meet, and there's no Yvienne to save her from her end. They are familiars, but she's always reliably there for Yvienne, while Yvienne is consistently the one who holds Larri's life on the line.

The Client depends on the Server to help them escape the ending of the world and certain death. In HS's canon, John dying too early meant there was no one to bring Jade into the game, result in her death and a failed session.

I can see a paralel here where there is a timeline Yvienne couldn’t save Larri, and maybe she did some cross-timelines shenanigans to save the alpha timeline. It succeed, but maybe their session was always meant to fail and Larri must die, and they can only win through other shenanigans (glitch? scratch?).

[ducktheverb]

"I was being selfish and that's why Larri left."

All my troubles on a burning pile All lit up and I start to smile If I catch fire then I'll change my aim Throw my troubles at the world again It goes, all my troubles on a burning pile All lit up and I start to smile If I, catch fire then I'll take my turn To burn and burn and burn

Mother Mother - Burning Pile

[clonetab]

Migrating your 𝗱𝗮𝘁𝗮𝗯𝗮𝘀𝗲𝘀 𝗮𝗻𝗱 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 to a new data center or the cloud just got easier with 𝗖𝗹𝗼𝗻𝗲𝘁𝗮𝗯’𝘀 𝗖𝗧-𝗟𝗔𝗦 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻! 🌐✨

🔹 𝗭𝗲𝗿𝗼 ���𝗼𝘄𝗻𝘁𝗶𝗺𝗲: Move your data without disrupting your operations. 🔹 𝗭𝗲𝗿𝗼 𝗗𝗮𝘁𝗮 𝗟𝗼𝘀𝘀: Safeguard your business-critical information with our secure, reliable solution. 🔹 𝗘𝗳𝗳𝗼𝗿𝘁𝗹𝗲𝘀𝘀 𝗠𝗶𝗴𝗿𝗮𝘁𝗶𝗼𝗻: Experience a smooth transfer with minimal effort and maximum efficiency. 🔹 Scalable & Secure: Whether on-prem or cloud-based, we ensure your migration is scalable, secure, and reliable.

From reducing manual efforts to boosting performance and uptime, CT-LAS gives you the power to migrate with confidence.

✅ Want a migration that’s hassle-free? Get in touch with us today!

[medicomunicare]

La via molecolare CTLA4-IL23: un dialogo insospettato che apre nuove possibilità contro cancro e autoimmunità

Il sistema immunitario ha molti percorsi per proteggere il corpo dalle infezioni, ma a volte una risposta immunitaria iperattiva provoca malattie autoimmuni tra cui le malattie infiammatorie intestinali (IBD), la psoriasi, l’artrite reumatoide e la sclerosi multipla. L’interleuchina-23 (IL-23) è uno di questi fattori immunitari che combatte le infezioni ma è anche implicato in molte di queste…

[moleculardepot]

Rabbit Polyclonal CTLA4 (E36-D161)) Antibody (Mouse, Rat)

Rabbit Polyclonal CTLA4 (E36-D161)) Antibody (Mouse, Rat) Catalog number: B2022145 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 100 ug Molecular Weight or Concentration: 24.993 kDa Supplied as: Lyophilized Applications: a molecular tool for various biochemical applications Storage: −20°C Keywords: Anti-CTLA-4 Antibody, CTLA-4 Inhibitor, CTLA-4 Antibody, Anti-Cytotoxic…

[arrangoiz]

Pathogenesis of Hashimoto’s Thyroiditis (HT)

A genetic predisposition for HT: Is evident in about 75% of cases Certain HLA class II antigens: Such as ARG74 in DR3: Carry an increased risk for the development of several autoimmune disorders thatinclude HT: With cytotoxic T-lymphocytes antigen-4 (CTLA-4) also playing a role A growing number of environmental factors: Have been implicated in the etiology of HT as well Interestingly,…

[businessindustry]

Checkpoint Inhibitor Refractory Cancer Treatment Market Forecast, Size, Share by 2024-2032 | Reports and Insights

The Reports and Insights, a leading market research company, has recently releases report titled “Checkpoint Inhibitor Refractory Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Checkpoint Inhibitor Refractory Cancer Treatment Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Checkpoint Inhibitor Refractory Cancer Treatment Market?

The global checkpoint inhibitor refractory cancer treatment market size reached US$ 35.6 billion in 2023. Looking forward, Reports and Insights expects the market to reach US$ 89.6 billion in 2032, exhibiting a growth rate (CAGR) of 10.8% during 2024-2032.

What are Checkpoint Inhibitor Refractory Cancer Treatment?

Checkpoint inhibitor refractory cancer treatment refers to therapeutic strategies designed for patients whose cancers do not respond to or progress despite treatment with immune checkpoint inhibitors, such as PD-1, PD-L1, or CTLA-4 inhibitors. These treatments focus on overcoming resistance mechanisms by employing alternative immunotherapies, such as bispecific antibodies, cancer vaccines, CAR-T cell therapies, or combination approaches with chemotherapy, targeted therapies, or radiation. Emerging strategies also include leveraging novel immune modulators, epigenetic therapies, and personalized medicine approaches to enhance immune response. This area of treatment addresses a critical unmet need, aiming to improve outcomes for patients with resistant or relapsed cancers.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2225

What are the growth prospects and trends in the Checkpoint Inhibitor Refractory Cancer Treatment industry?

The checkpoint inhibitor refractory cancer treatment market growth is driven by various factors and trends. The checkpoint inhibitor refractory cancer treatment market is gaining momentum due to the increasing prevalence of cancers resistant to immune checkpoint inhibitors like PD-1, PD-L1, and CTLA-4 inhibitors. Key drivers include growing research into novel immunotherapies, such as bispecific antibodies, CAR-T cell therapies, and personalized cancer vaccines, aimed at overcoming treatment resistance. Advancements in combination therapies that integrate checkpoint inhibitors with chemotherapy, radiation, or targeted drugs are also fueling market growth. Rising investments in oncology R&D, the expansion of clinical trials, and the increasing adoption of precision medicine approaches further propel the market. This segment addresses a critical unmet need, offering hope for improved outcomes in refractory and relapsed cancers. Hence, all these factors contribute to checkpoint inhibitor refractory cancer treatment market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Application

Hodgkin Lymphoma

Kidney Cancer

Melanoma

Non-Small Cell Lung Cancer

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

AstraZeneca

Merck

Genentech/Hoffmann-La Roche

Regeneron Pharmaceuticals

Merck KGaA and Pfizer

Bristol-Myers Squibb

Janssen Research and Development, LLC

4D pharma plc.

4SC AG

OncoSec Medical

Mirati Therapeutics

View Full Report: https://www.reportsandinsights.com/report/Checkpoint Inhibitor Refractory Cancer Treatment-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[cobaltsunflower]

*sigh deeply* perhaps for a short moment they could have had sth good

[ducktheverb]

Normalize making memes for dead fandoms!!!

(I think it’d be really funny if:

They are a throuple

Yvienne likes playing around

They are really supportive

But she has Really Bad taste)

.

References:

This drawing inspired the meme, and the girls are wearing sth like the dresses below

In a Roman Osteria by Carl Bloch

[globalinsightblog]

Immune Checkpoint Inhibitor Market: $25.5B in 2023 to $67.8B by 2033, 10.2% CAGR

Immune Checkpoint Inhibitor Market is at the forefront of transforming cancer treatment, focusing on therapies that block proteins suppressing immune responses against cancer cells. This market primarily includes monoclonal antibodies targeting key pathways like CTLA-4, PD-1, and PD-L1, which have revolutionized oncology by enhancing the body’s immune response to combat cancer.

To Request Sample Report: https://www.globalinsightservices.com/request-sample/?id=GIS26260 &utm_source=SnehaPatil&utm_medium=Article

In 2023, the market exhibited a robust distribution of approximately 750 million units globally, with PD-1/PD-L1 inhibitors leading with a 65% market share. These inhibitors are widely recognized for their efficacy across various cancer types, driving their dominant position. CTLA-4 inhibitors secure the second spot with a 25% share, particularly noted for their role in combination therapies that enhance treatment outcomes. The remaining 10% includes emerging therapies like LAG-3 inhibitors, reflecting the ongoing innovation within this field.

North America stands as the leading region, attributed to its advanced healthcare infrastructure and significant investments in immunotherapy research. The United States spearheads this growth, supported by a strong pharmaceutical industry and numerous clinical trials. Europe follows closely, benefiting from rising cancer incidences and favorable regulatory policies, with Germany playing a pivotal role due to its robust biotech sector.

Asia-Pacific is emerging as a substantial market, driven by increasing healthcare expenditures and large patient populations in countries like China and Japan. These nations are advancing through strategic collaborations and expanding healthcare access, positioning the region for significant growth in the coming years.

The market’s evolution is characterized by strategic partnerships, expanding therapeutic indications, and continuous innovations in checkpoint inhibitor therapies. As cancer prevalence rises globally, the demand for effective immune checkpoint inhibitors is expected to surge, offering significant opportunities for advancements in precision medicine and personalized healthcare solutions.

#ImmuneCheckpointInhibitors #CancerImmunotherapy #PD1Inhibitors #PDL1Inhibitors #CTLA4Inhibitors #OncologyInnovation #PrecisionMedicine #CancerTreatment #ImmunoOncology #CheckpointInhibitors #BiotechBreakthroughs #HealthcareInnovation #PersonalizedTherapy #ClinicalTrials #CancerResearch

[psychicsheeparcade]

Immunohistochemistry Market Share, Size, Demand, Key Players by Forecast 2034

The Immunohistochemistry (IHC) market is a rapidly growing segment in the field of life sciences, driven by advancements in diagnostic techniques, increasing prevalence of chronic diseases, and rising demand for personalized medicine. IHC is a technique used to detect specific antigens in tissue samples by employing antibodies, enabling researchers and clinicians to gain insights into disease mechanisms, tumor classification, and therapeutic targets.

The global immunohistochemistry market is expected to reach USD 7.95 billion in 2034 based on average growth. Additionally, the analysis projects that between 2024 and 2034, the market would expand at a compound annual growth rate (CAGR) of 7.5%. It is projected that the worldwide immunohistochemistry industry would bring in USD 3.68 billion by 2024. 

Get a Sample Copy of Report, Click Here@  https://wemarketresearch.com/reports/request-free-sample-pdf/immunohistochemistry-market/1595

Immunohistochemistry Market Drivers

Rising Incidence of Cancer: IHC plays a pivotal role in cancer diagnosis and prognosis by providing insights into tumor origin and progression. The increasing prevalence of cancer globally is a significant driver for the market.

Advancements in Diagnostic Techniques: Technological advancements, such as automated staining systems and digital pathology, have improved the accuracy and efficiency of IHC, making it a preferred diagnostic tool.

Growth in Personalized Medicine: IHC is extensively used to determine biomarker expression levels, aiding in targeted therapies and personalized treatment plans.

Expansion of Healthcare Infrastructure: Emerging markets are witnessing significant investments in healthcare infrastructure, leading to greater adoption of advanced diagnostic tools like IHC.

Immunohistochemistry  Market Challenges

High Costs of IHC Instruments and Reagents: The cost of setting up IHC labs and procuring antibodies and reagents can be prohibitive, especially for smaller healthcare facilities.

Limited Skilled Workforce: Performing IHC tests requires expertise, and the shortage of trained professionals can hinder market growth.

Immunohistochemistry Market Opportunities

Growth in Emerging Markets: Developing countries in Asia-Pacific and Latin America are investing heavily in healthcare, creating lucrative opportunities for IHC manufacturers.

Integration with Artificial Intelligence (AI): AI-powered image analysis tools are being integrated with IHC to enhance diagnostic precision and reduce human error.

Emerging Trends in the IHC Market

Multiplex Immunohistochemistry (mIHC):

Enables simultaneous detection of multiple biomarkers within a single tissue sample, offering deeper insights into complex diseases like cancer and immune disorders.

Growing demand in immuno-oncology research and drug development.

Integration of Digital Pathology:

Adoption of whole-slide imaging and AI-powered diagnostic solutions to enhance workflow efficiency and diagnostic accuracy.

Facilitates remote consultations and second opinions through telepathology.

Companion Diagnostics:

Growing use of IHC in companion diagnostics to identify patients likely to benefit from specific therapies, particularly in oncology.

Examples include HER2 testing in breast cancer and PD-L1 testing in immunotherapy.

Automated Systems and Robotics:

Increasing use of automated staining platforms for faster processing and reduced manual errors.

Innovations like on-board reagent management systems to enhance lab productivity.

Emergence of Novel Biomarkers:

Identification of new biomarkers for complex diseases, expanding the scope of IHC applications.

Significant focus on immune checkpoint biomarkers such as CTLA-4 and LAG-3.

Immunohistochemistry Key  Market Players 

The Immunohistochemistry Market is dominated by a few large companies, such as

F. Hoffmann-La Roche Ltd

Agilent Technologies, Inc.

Danaher Corporation (Leica Biosystems)

Thermo Fisher Scientific Inc.

Merck KGaA (MilliporeSigma)

Bio-Rad Laboratories, Inc.

Abcam plc

Biocare Medical, LLC

Cell Signaling Technology, Inc. (CST)

PerkinElmer Inc.

Sakura Finetek Japan Co., Ltd.

Becton, Dickinson and Company (BD)

Immunohistochemistry Market Segments

By Product

Antibodies

Kits

REAGENTS

By End-User

Hospitals

Academic

Diagnostic Labs

By Application

Forensic

Diagnostic

Research

Immunohistochemistry Industry: Regional Analysis

 North American market's forecast

North America was the largest market in the world in 2023, with more than 38% of the worldwide market. The region's supremacy is attributed to a number of factors, including a stable healthcare system, the presence of significant market participants, a strong emphasis on cancer research and individualized treatment, and the widespread use of state-of-the-art diagnostic techniques. The United States and Canada are the two countries that provide the largest contributions to this industry.  

Asia-Pacific Market Forecasts

Increased investment in healthcare infrastructure, a growing demand for individualized care, and growing awareness of early cancer detection are the primary drivers of growth in this field. The leading contributors to the regional market are South Korea, Japan, India, and China. The huge patient base and the increasing number of pharmaceutical and biotechnology companies in this sector present numerous opportunities for market growth.    

Market Statistics for Europe

The market is growing in this sector due to a number of factors, including rising healthcare expenses, the incidence of chronic illnesses, and a strong focus on research and development in nations like the UK, France, and Germany. Favorable reimbursement and regulatory environments also contribute to the growth of the European IHC market.  

FAQs on the Immunohistochemistry (IHC) Market

1. What is Immunohistochemistry (IHC)?

2. What are the primary applications of IHC?

3. Why is IHC important in cancer diagnosis?

4. What are the main products used in IHC?

5. What are the latest advancements in the IHC market